BioNxt's Sublingual Cladribine Program for MS Ready for Next Phase
The delivery of the cladribine API enables the commencement of clinical batch manufacturing in collaboration with BioNxt's European contract research and development partner, Gen-Plus GmbH & Co KG, based in Munich, Germany. This milestone supports the company's plan to initiate a human bioequivalence study in the second half of 2025.
BNT23001 is designed to offer a patient-friendly alternative to traditional oral cladribine tablets, such as Mavenclad®, by providing a rapidly dissolving sublingual film. This delivery method aims to enhance patient compliance, particularly for individuals with MS who experience dysphagia, a common symptom affecting the ability to swallow.
Preclinical studies have demonstrated that BNT23001 achieves high absorption rates and bioequivalence to existing oral therapies, with no adverse toxic effects observed. These findings support the progression to human bioequivalence studies.
BioNxt has also made significant strides in securing intellectual property rights for BNT23001. The company has initiated patent nationalization processes in key jurisdictions, including Europe, the United States, and Canada, with patent grants anticipated by mid-2025.
'The receipt of the cladribine API is a pivotal step forward in our mission to develop innovative, patient-centric therapies for MS,' said Hugh Rogers, CEO of BioNxt Solutions. 'We are committed to advancing BNT23001 through clinical development and bringing this novel treatment option to patients worldwide.'
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next‐generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin‐Film), Transdermal (Skin Patch), and Oral (Enteric‐Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient‐centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com .
Investor Relations & Media Contact
Hugh Rogers, Co‐Founder, CEO and Director
Email: [email protected]
Phone: +1 778.598.2698
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt‐solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding 'Forward‐Looking' Information
This news release includes certain statements that may be deemed 'forward-looking statements'. All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words 'expects', 'plans', 'anticipates', 'believes', 'intends', 'estimates', 'projects', 'potential' and similar expressions, or that events or conditions 'will', 'would', 'may', 'could' or 'should' occur. Forward-looking information in this news release includes the anticipated filing date of the Annual Filings. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
SOURCE: BioNxt Solutions Inc.
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Wall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth
July 11 -Eli Lilly (NYSE:LLY) drew attention on Friday after JPMorgan reiterated its bullish stance on the stock, raising its price target to $1,100 and citing strong momentum in the company's obesity treatment portfolio Analyst Chris Schott pointed to continued strength in sales of Mounjaro and Zepbound, with the latter accounting for roughly 75% of new treatment starts despite its removal from CVS Health's (CVS) preferred drug list. JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in the category. The brokerage sees long-term growth potential driven by next-gen drugs, including orforglipron, a pill-based GLP-1 treatment in development, and the late-stage candidate retatrutide, referred to as Triple G. Patent coverage into the 2030s reduces risk of near-term exclusivity losses, the note said, adding that earnings could surpass $55 per share by 2030, up from $13 in 2023. Strong pipeline momentum and durable patent coverage continue to bolster investor confidence. Based on the one year price targets offered by 26 analysts, the average target price for Eli Lilly and Co is $967.78 with a high estimate of $1190.00 and a low estimate of $675.00. The average target implies a upside of +22.40% from the current price of $790.65. Based on GuruFocus estimates, the estimated GF Value for Eli Lilly and Co in one year is $1218.37, suggesting a upside of +54.10% from the current price of $790.65. Gf value is Gurufocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. For deeper insights, visit the forecast page. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Wall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth
July 11 -Eli Lilly (NYSE:LLY) drew attention on Friday after JPMorgan reiterated its bullish stance on the stock, raising its price target to $1,100 and citing strong momentum in the company's obesity treatment portfolio Analyst Chris Schott pointed to continued strength in sales of Mounjaro and Zepbound, with the latter accounting for roughly 75% of new treatment starts despite its removal from CVS Health's (CVS) preferred drug list. JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in the category. The brokerage sees long-term growth potential driven by next-gen drugs, including orforglipron, a pill-based GLP-1 treatment in development, and the late-stage candidate retatrutide, referred to as Triple G. Patent coverage into the 2030s reduces risk of near-term exclusivity losses, the note said, adding that earnings could surpass $55 per share by 2030, up from $13 in 2023. Strong pipeline momentum and durable patent coverage continue to bolster investor confidence. Based on the one year price targets offered by 26 analysts, the average target price for Eli Lilly and Co is $967.78 with a high estimate of $1190.00 and a low estimate of $675.00. The average target implies a upside of +22.40% from the current price of $790.65. Based on GuruFocus estimates, the estimated GF Value for Eli Lilly and Co in one year is $1218.37, suggesting a upside of +54.10% from the current price of $790.65. Gf value is Gurufocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. For deeper insights, visit the forecast page. This article first appeared on GuruFocus.
Yahoo
3 hours ago
- Yahoo
YVR celebrates additional Asia-Pacific connections with inaugural T'way flight to Seoul
New carrier strengthens YVR's position as a global gateway, key driver of trade and economic impact MUSQUEAM TERRITORY and RICHMOND, BC, July 12, 2025 /CNW/ - Vancouver International Airport (YVR) is proud to be the first airport in North America to welcome regular service from South Korean airline, T'way Air. Today's inaugural flight kicks off four-times weekly, year-round service between Incheon International Airport (ICN) in Seoul and YVR, further positioning YVR as the preferred North American gateway to Asia-Pacific. The new T'way service provides the community with even more flexibility and convenience when travelling to South Korea and connections across Asia, but the benefits of this new service go beyond passengers alone. An additional air connection provides increased cargo capacity to further diversify trading markets and get British Columbian and Canadian products to consumers in Asia and around the world. 2024 was a record-breaking year for cargo out of YVR with more than 339,000 tonnes of goods shipped through the airport and South Korea is YVR's number two air export destination. "British Columbia has long had strong ties with South Korea and is home to a large Korean community that continues to make significant contributions to the cultural diversity and prosperity of our province," said B.C. Premier David Eby. "This affordable direct flight will allow people to stay connected with friends and family across the Pacific and also means that it will be faster and easier to do business with our fourth largest trading partner, strengthening the economic ties between us during a time of global uncertainty." "This new service to South Korea is about more than travel convenience—it represents a strategic investment in connectivity, trade, and Canada's place in the global economy," said Tamara Vrooman, President and CEO at YVR. "YVR is excited to further expand our ability to connect Canada with the world, to support industry and families, attract investment, and to further build resilience in supply chains." Each new international route from YVR results in direct economic benefit, with the flight to Seoul estimated to generate $39.8 million in economic output, $20.8 million in GDP, and 237 full time jobs in the province. "The launch of our Vancouver–Incheon route represents more than just a new destination—it's a meaningful bridge connecting people, cultures, and economic opportunity," said Mr. Sang Yoon Lee, CEO of T'way Air. "As the first Korean low-cost carrier to serve Canada, we're excited to welcome onboard travellers to Korea while continuing to deliver reliable service." Prior to the flight departing for its inaugural 11-hour journey, Elders from Musqueam, joined by Musqueam Councillor Morgan Guerin, helped send passengers on their journey in a good way with traditional songs and hands raised. Since 2017, this relationship has been guided by the Musqueam-YVR Sustainability & Friendship Agreement, a 30-year commitment built on respect, reconciliation, and shared prosperity. Flights with T'way from Vancouver to Seoul are scheduled to depart YVR at 5:25 p.m. local time arriving at ICN the next day at 9:35 p.m. local time. T'way is operating this route using an Airbus 330-300 aircraft, offering 347 seats, including lie-flat options in its Business Saver class, moving approximately 2,700 passengers weekly. Established in 2010, T'way Air is a low-cost carrier serving more than 40 destinations domestically in South Korea and around the globe including Europe, Asia, Australia, and now North America with the introduction of service to YVR. For further details on this new service and to book, please visit Photos and B-roll footage of the departure celebrations at YVR are available upon request by contacting media_relations@ ABOUT YVR Vancouver International Airport (YVR) is a diverse global hub that connects people, cargo, data, and ideas and serves as a platform for our community to come together and thrive. We are motivated by supporting regional economic development and making a positive difference in the lives of British Columbians. We do this with a focus on serving our passengers, partners, workers, and community through digital modernization, climate leadership, reconciliation, and financial sustainability. For media queries please contact: YVR Media Relations, 604-880-9815, media_relations@ SOURCE Vancouver Airport Authority View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
